Viking Therapeutics, Inc. VKTX
26.88 USD +0.08 (+0.30%)
Regular-session close
27.44 +0.56 +2.07%
After hours · Nov 17, 7:59 PM ET
26.48 Day range 28.49
23.82 52-week range 43.10
- YTD
- -23.59%
- 1 year
- -29.67%
News
fool.com Viking: 3 Key Takeaways for Long-Term Investors Dosing flexibility across weekly, biweekly, and monthly schedules gives Viking a structural advantage that currently approved competitors don't yet offer.
benzinga.com Viking Therapeutics Stock Dips Despite Positive VK2735 Data: What’s Going On? Shares of Viking Therapeutics Inc (NASDAQ:VKTX) are down about 5% on Monday. The stock is trending as traders digest a fresh update on the company’s VK2735 under-the-skin injection program.benzinga.com Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 WeeksVK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers
gurufocus.com Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek 2026PR NewswireSAN DIEGO, Nov. 15, 2026VENTURE Analysis Finds 74% of P
prnewswire.com Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic…
benzinga.com AMD Sinks 10.5% as Chip Rally Unwinds, Nasdaq 100 Falls 1.7%: Stock Market Today AMD lost about $100 billion as traders unwound the post-Huang chip rotation, Nvidia's China scandal deepened and Cisco slid on margins. QQQ fell 1.7%.
zacks.com 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
fool.com Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028 Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.
fool.com Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company,…
fxempire.com Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55 Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.
zacks.com Novo Up 4% in a Month: How Should Investors Approach the Stock Now? NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
prnewswire.com Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the…
fool.com Here's the 1 Stock I'd Most Want to Buy If the Market Crashes Viking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.
fool.com Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.
fool.com How I'd Invest $10,000 Right Now Tracking the S&P 500 may not be optimal anymore, and there can be better ways for investors to gain a mix of dividends, stability, and growth.
prnewswire.com Viking Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and…
fool.com UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. UBS sees approximately 250% upside potential for Viking shares over the next year. Viking's weight loss candidates could compete effectively with the established drugs from Eli Lilly and Novo Nordisk.benzinga.com Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118 Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $118.
zacks.com VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach? Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
zacks.com Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
seekingalpha.com Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet) Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for…
zacks.com VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
zacks.com VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.
benzinga.com Viking Therapeutics Stock Jumps: What's Going On? Viking Therapeutics Inc (NASDAQ:VKTX) shares are popping Thursday. The obesity drug developer reported third-quarter results that paired a wider-than-expected loss with positive study data and a $960…
247wallst.com Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…benzinga.com Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106 Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.
